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ABSTRACT
Objective There is evidence that natural killer (NK) cells
help control persistent viral infections including hepatitis
C virus (HCV). The phenotype and function of blood and
intrahepatic NK cells, in steady state and after interferon
(IFN) α treatment has not been fully elucidated.
Design We performed a comparison of NK cells derived
from blood and intrahepatic compartments in multiple
paired samples from patients with a variety of chronic
liver diseases. Furthermore, we obtained serial paired
samples from an average of ﬁve time points in HCV
patients treated with IFNα.
Results Liver NK cells demonstrate a distinct activated
phenotype compared to blood manifested as
downregulation of the NK cell activation receptors CD16,
NKG2D, and NKp30; with increased spontaneous
degranulation and IFN production. In contrast, NKp46
expression was not downregulated. Indeed, NKp46-rich
NK populations were the most activated, correlating
closely with the severity of liver inﬂammation. Following
initiation of IFNα treatment there was a signiﬁcant
increase in the proportion of intrahepatic NK cells at days
1 and 3. NKp46-rich NK populations demonstrated no
reserve activation capacity with IFNα treatment and were
associated with poor viral control on treatment and
treatment failure.
Conclusions NKp46 marks out pathologically activated
NK cells, which may result from a loss of homeostatic
control of activating receptor expression in HCV.
Paradoxically these pathological NK cells do not appear
to be involved in viral control in IFNα-treated individuals
and, indeed, predict slower rates of viral clearance.
INTRODUCTION
Hepatitis C virus (HCV) chronically infects 3% of
the global population and represents a major global
health problem. Although adaptive immune
responses contribute to controlling and clearing
acute HCV infection,1 2 it is clear that other
branches of the immune response are important for
viral control. Natural killer (NK) cells are large
granular cytotoxic lymphocytes, phenotypically
deﬁned as CD3− CD56+, which play an important
role in controlling viral infections. NK cells express
a combination of activating and inhibitory recep-
tors, and are functionally triggered when signalling
from activating receptors overcomes that of inhibi-
tory receptors. Activating receptors include the
FcγIII receptor CD16, natural cytotoxicity recep-
tors such as NKp30 and NKp46, and NKG2D, a
C-type lectin-like receptor. There is some evidence
that NK cells play a protective role in individuals
exposed to HCV.3 4 However, there is no consensus
between multiple studies of NK cell receptor
phenotype in chronic HCV infection. Separate indi-
vidual studies examining receptors such as NKp30,
Signiﬁcance of this study
What is already known on this subject?
▸ NK cells form part of the innate immune
response to viral infections including HCV.
▸ There are very limited data regarding the role
of intrahepatic NK cells in chronic HCV
infection and during IFNα-based treatment.
▸ NKp46 expression, a NK cell-activating
receptor, has been associated with increased
NK cell activity in HCV infection but in mouse
models lower NKp46 expression has been
associated with rapid NK cell control of viral
infections.
What are the new ﬁndings?
▸ Increased NKp46 expression is associated with
increased NK cell cytotoxic activity ex vivo in
HCV-infected individuals but not healthy
controls.
▸ NK cells are more activated in the intrahepatic
compartment. NKp46 expression and NK cell
cytotoxic activity correlates with liver
inﬂammation. Failure of homeostatic NKp46
downregulation following NK cell activation in
chronic HCV appears to drive liver pathology.
▸ During IFNα treatment rapid viral clearance and
treatment success are associated with lower
pretreatment expression levels of NKp46.
How might it impact on clinical practice in
the foreseeable future?
▸ High NKp46 expression in chronic HCV
infection identiﬁes individuals most at risk of
liver inﬂammation and at increased risk of
failing IFNα-based treatment.
▸ NKp46 provides a novel treatment target—
reducing NKp46 expression may reduce
inﬂammation in patients unsuitable for
treatment and transient reduction before
treatment may increase SVR rates.
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NKp46, and NKG2D have variously reported upregulation,5–7
downregulation8 9 or no change10 11 in HCV infection com-
pared to healthy controls.
A similar lack of consensus emerges regarding the degree of
preservation of cytotoxic function of NK cells in HCV.5 6 10 12
A recent study demonstrated that NKp46High NK cells have
greater cytotoxic activity and interferon (IFN) production,
allowing control of viral replication albeit using an in-vitro
model.13 However, others found that NK cells retrieved from
the intrahepatic compartment demonstrate a reduced cytotoxic
function ex vivo.14 Key questions remain regarding how intrahe-
patic NK cell phenotype impinges on function, HCV pathogen-
esis and the successful treatment of HCV. Current treatment for
HCV is based on IFNα injections. NK cells are stimulated by
IFNα but the role of NK cells and their action during
IFNα-based treatment is not clear. Most studies to date investi-
gating the role of NK cells in HCV treatment have focused on
peripheral blood rather than the intrahepatic compartment, but
a major problem in interpreting these studies lies in not
knowing whether NK cell function in blood reﬂects that of
intrahepatic NK cells.
In this study we investigated NK cell function, using multi-
parameter ﬂow cytometry, not only in matched blood and intra-
hepatic samples, but also by obtaining repeat serial liver biopsies
(ﬁne needle aspirations; FNA) in individuals who were being
actively treated with IFNα. NK cell function was compared
between individuals with HCV, other chronic liver diseases
(CLD), or healthy controls. The questions we set out to address
include: (1) Does chronic inﬂammation of the liver per se affect
NK cell function? (2) Does chronic HCV infection impinge on
NK cell function and phenotype in the blood and the liver? (3)
Do the results obtained from blood reﬂect the results from liver
samples? (4) Would NK cell phenotype and function predict
response to treatment of HCV with IFNα?
MATERIALS AND METHODS
Cohort
Fifty-seven patients (35 consecutive patients with chronic HCV
and 22 patients with non-viral CLD) attending University Hospital
Wales were enrolled (table 1 and supplementary table, available
online only). Positive anti-HCV antibodies and HCV RNA identi-
ﬁed by reverse transcriptase PCR at two time points at least
6 months apart conﬁrmed chronic HCV infection. Treated patients
received pegylated-IFNα and ribavirin for 6–12 months depending
on virus genotype. Treatment success is deﬁned as sustained virus
response (SVR) demonstrated by negative PCR tests both immedi-
ately after and at 6 months after treatment. A single consultant
histopathologist assessed the biopsy samples according to Ishak
necroinﬂammatory score (0–18) and ﬁbrosis stage (0–6).15
Degranulation assays
CD107a externalisation on NK cell degranulation was used as a
marker of NK cell cytotoxic activity.16 Frozen peripheral blood
mononuclear cell (PBMC) samples were obtained from 23
chronic HCV patients pretreatment (see supplementary table,
available online only), 13 healthy donors (HD) and 10 CLD
donors. Cells were thawed, washed and cultured overnight at
106/ml in RPMI media–10% fetal bovine serum with 0, 50 or
1000 IU/ml IFNα (Roferon, Roche, UK). PBMC were washed
and exposed to Huh7.5 (human hepatoma cell line) or K562
(erythroleukaemic cell line lacking in MHC class I) target cells in
DMEM–10% fetal bovine serum (E:T ratio=5 : 2) with
CD107a-PE (BD Biosciences, Oxford, UK) for 4 h and 1 μl of
Golgi stop (BD Biosciences) for the ﬁnal 3 h. Non-adherent cells
were washed and stained with Aqua live/dead stain (Invitrogen,
Paisley, UK) and ﬂuorochrome labelled monoclonal antibodies
speciﬁc for CD3-APCH7, CD14-APCH7, CD19-APCH7 (BD
Biosciences), CD16-FITC, NKG2D-APC, NKp30-Biotin
(Miltenyi Biotech, Bisley, UK), streptavidin-PECy7 (eBioscience,
Hatﬁeld, UK), CD56-PerCP.Cy5 and NKp46-PB (Biolegend,
Cambridge, UK). Cells were washed, ﬁxed with 2% paraformal-
dehyde solution and analysed by ﬂow cytometry using a CyAn
ADP ﬂow cytometer (Beckman-Coulter). The data were analysed
using FlowJo software (Ashland, Oregon, USA). We compared
the ratio of CD107a upregulation with a strong stimulus (K562
cells plus 1000 IU/ml IFNα) to a weak stimulus (Huh7.5 cells
plus 50 IU/ml IFNα), that is, functional ratio=% NK cells expres-
sing CD107a with strong stimulus÷% NK cells expressing
CD107a with a weak stimulus, as described previously17 and illu-
strated in supplementary ﬁgure S5 (available online only).
The expression of NK cell-activating receptor ligands on
Huh7.5 and K562 cells was analysed by ﬂow cytometry using
NKp30 and NKp46–human Fc fusion proteins (R&D Systems,
Abingdon, UK) and anti-human FcγPE antibody (eBioscience);
and mouse monoclonal antibodies (BAMOMAB, Munich,
Germany) to the NKG2D ligands (MICA, MICB and ULBP2)
and anti-mouse-AF647 secondary antibody (Invitrogen).
Table 1 Donor characteristics
Characteristics HCV Chronic liver disease HCV donating FNA HCV donating PBMC for cytotoxicity experiments
Number 35 22 24 23
Mean age (range) 48 (27–67) 50.6 (29–69) 49 (27–65) 45.7 (27–67)
Male:female 25 : 10 12 : 10 17 : 7 15 : 8
Median viral load (range) 1.45×106 (1.9×103–3×107) – 1.3×106 (1.9×103–3×107) 7.5×105 (3.1×103–3×107)
Median NI score (range)* 5 (0–8) 1 (0–6) 5 (2–8) 5 (0–8)
Median fibrosis score (range)* 2 (0–6) 2 (0–6) 2 (0–2) 2 (1–6)
HCV genotype
1 17 – 16 9
3 15 – 8 11
4 1 – – 1
5 1 – – 1
1&3 1 – – 1
*Necroinflammatory and fibrosis scores according to Ishak criteria.
FNA, fine needle aspiration; HCV, hepatitis C virus; NI, necroinflammatory; PBMC, peripheral blood mononuclear cell.
2 Pembroke T, et al. Gut 2013;0:1–10. doi:10.1136/gutjnl-2013-304472
Viral hepatitis
Intrahepatic NK cell samples
Intrahepatic NK cells were sampled by FNA of the liver from
46 consecutive patients (24 HCV and 22 CLD controls) attend-
ing for pretreatment liver biopsy (table 1). Two per cent ligno-
caine was inﬁltrated, a 22 gauge spinal needle (Becton
Dickinson, Madrid, Spain) was inserted and a single cell suspen-
sion aspirated into RPMI 10% foetal calf serum (FCS) with
250 μl heparin on ice. Intrahepatic samples are essentially intra-
capsular and due to the exceptionally vascular nature of the
liver, will inevitably include lymphocytes from the small sinu-
soids as well as the intracellular space. However, heavily blood-
stained aspirates were discarded and the needle passed into
fresh liver. Paired peripheral blood samples were taken and lym-
phocytes were separated by lymphoprep density gradient.
Samples were washed twice in phosphate-buffered saline and
stained as above and in addition antibodies for CD107a-FITC
(Miltenyi Biotech), and NKG2A-PE (R&D Systems). Cells were
then permeabilised and ﬁxed (Fix/Perm; eBioscience) and
stained with antibodies to Granzyme B-APC (Invitrogen),
Ki67-PE (Biolegend) and IFNγ-e450 (eBioscience). Cells were
washed, ﬁxed and analysed by ﬂow cytometry as described
above. Nine patients agreed to repeated FNA and peripheral
blood sampling during IFNα treatment. Sampling time points
were pretreatment, days 1 and 3; weeks 1, 2, 4 and 12.
Viral load analysis
HCV RNA was quantitated by reverse transcriptase PCR (detec-
tion down to 30 copies per ml), Cobas Ampliprep/Cobas
Taqman HCV test (Roche Diagnostic Systems). Lab21
(Cambridge, UK) undertook this work.
Immunohistochemistry
Fixed and mounted liver biopsy specimens taken from
HCV-infected patients were dewaxed and antigen retrieval per-
formed. Endogenous peroxidase activity was suppressed with
Peroxidase Suppressor (Thermo Scientiﬁc) and sections blocked
with 2.5% normal horse serum (Vectorlabs). Sections were
stained overnight with goat anti-NKp46 (Vector) and rabbit
anti-CD3 (DakoCytomation) antibodies diluted in 1% bovine
serum albumin, detected with anti-goat or anti-rabbit Immpress
and visualised with 3, 30-diaminobenzidine (DAB) (VectorLabs).
Sections were counterstained with haematoxylin, dehydrated and
mounted with Dpex (Panreac Life Sciences, Barcelona, Spain).
Photomicrographs were taken using a Nikon microscope.
Statistical analysis
A comparison of phenotypic and functional markers was made
using Student’s t test assuming normal distribution of data. The
kinetic parameters of viral clearance (rate constant k in day−1)
were calculated from a non-linear regression curve best ﬁt
(y=y0e
−kx+plateau; y0=viral concentration day 0, plateau=ﬁnal
viral concentration after treatment). Comparison of NK func-
tional markers with activation markers and rate of viral clear-
ance was by linear regression. Comparison of non-parametric
data and NK markers was by Spearman’s r analysis. Software
employed was Excel 2011 and GraphPad Prism V.5.0.
RESULTS
Patient demography
Thirty-ﬁve patients with chronic HCV infection and 22 CLD
patients were recruited (summarised in table 1 and individual
data in the supplementary table, available online only). Twenty
four patients completed combined IFNα and ribavirin treat-
ment; seven failed to clear the virus and 17 achieved SVR.
NK cell frequency, phenotype and function in the blood
of patients with chronic HCV.
The frequency and phenotype of NK cells in blood samples
taken from patients with chronic HCV infection, CLD and
healthy controls was compared. NK cells were deﬁned as single
live cells within the lymphocyte gate, which were CD56+ yet
CD3− CD14− and CD19− to exclude T cells, monocytes and
B cells, respectively (see supplementary ﬁgure S1A–D, available
online only). The proportion of lymphocytes that were NK cells
was slightly lower in the HCV cohort (more marked for geno-
type 1 patients, data not shown) compared to HD (mean 10.1%
vs 13.3% p=0.05; ﬁgure 1A). Perhaps surprisingly, despite the
presence of chronic HCV infection, the phenotype of blood NK
cells (eg, CD56Bright:Dim ratio, expression of CD16, NKp30,
NKG2D and CD107a) does not differ signiﬁcantly to HD (data
not shown). There was a slight reduction in the percentage of
NKp46+ cells in the HCV cohort compared to HD (mean
72.1% vs mean 80.6% p=0.06; ﬁgure 1B).
Following stimulation of NK cells with the weak stimulus
(Huh7.5 cells plus 50 IU/ml IFNα), NK cell degranulation as
measured by CD107a was signiﬁcantly reduced in the HCV
cohort compared to HD and CLD donors. Following stimulation
with a stronger stimulus (K562 cells plus 1000 IU/ml IFNα) NK
cell degranulation was reduced in both the HCV patients and
CLD controls compared to HD (ﬁgure 1C). Intriguingly, the NK
cell activation in vitro strongly correlated to the percentage
NKp46+ cells in the HCV cohort (p=0.0068, r2=0.29; ﬁgure
1D, left panel panel) but not the HD or CLD donors (ﬁgure 1D,
right panel). No such correlations were observed for other acti-
vating receptors (CD16, NKp30 and NKG2D; data not shown).
Expression of the ligands for NKp30, NKp46 and NKG2D on
Huh7.5 and K562 targets was examined by ﬂow cytometry.
Ligands for NKp30 and NKG2D were expressed at far higher
levels on K562 cells than Huh7.5 cells, in line with their superior
ability to stimulate NK cells. Conversely, NKp46 ligands,
although expressed at comparatively low levels, were nevertheless
better expressed on the Huh7.5 cells than K562 cells (see supple-
mentary ﬁgure S2A,B, available online only). Therefore, altera-
tions in NKp46 expression (ie, NKp46-rich vs NKp46-low cells)
is more likely to impact on killing of Huh7.5 than K562 cells, as
suggested by the data shown in ﬁgure 1D (and see ﬁgure 4C).
In summary, although the pattern of expression of markers
on blood-derived NK cells is not strikingly different in
HCV-infected subjects, their cytotoxic function was signiﬁcantly
reduced. These data also suggest NKp46 plays a particular role
in the pathobiology of NK cells in HCV infection.
Intrahepatic NK cells demonstrate an activated phenotype
compared to blood-derived population in patients with CLD
To assess NK cells within the intrahepatic compartment we
obtained multiple samples from 24 HCV patients and 22 CLD
patients. The overall frequencies of NK cells were strikingly
similar between blood-derived and intrahepatic populations
(ﬁgure 2A, left panel), with the frequencies between the two
compartments strongly correlating (HCV infection p=0.0007,
r2=0.4; CLD p=0.024, r2=0.23; ﬁgure 2A, right panel). These
data suggest that the reduction in NK proportion in HCV com-
pared to HD (ﬁgure 1A) is not related to a migration of NK
cells to the inﬂamed liver.
Activating NK cells experimentally in vitro results in both
degranulation (CD107a externalisation, ﬁgure 1C) and
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downregulation of cell surface NK activating receptors (eg,
CD16, NKp30, NKp46 and NKG2D, see supplementary ﬁgure
S3A–D, available online only). Detailed ex-vivo phenotypic ana-
lyses, without restimulation, conﬁrm that intrahepatic NK cells
have been activated in situ indicated by a highly signiﬁcant
downregulation in CD16 and NKp30 in HCV and CLD groups
(p < 0.0001; ﬁgure 2B,C); downregulation in NKG2D expres-
sion (HCV cohort only p=0.01; ﬁgure 2D); and signiﬁcantly
increased expression of IFN-γ and CD107a with decreased
intracellular granzyme B (p<0.006; ﬁgure 2F–I).
NKp46 was again distinguished from other activation markers
as it did not show evidence of being downregulated within the
liver, that is, the frequencies of NKp46+ NK cells in the blood
and liver compartments were the same (ﬁgure 2E, left panel),
with a highly signiﬁcant correlation between the levels found in
these compartments (p<0.0001, r2=0.68; ﬁgure 2E, right
panel). HCV-infected subjects demonstrate higher levels of
NKp46 in both blood and liver compared to CLD controls
(ﬁgure 2E); and also slightly higher levels of NKp30 (ﬁgure 2C)
and NKG2D (ﬁgure 2D). Furthermore, NKp46+ NK cell fre-
quencies appeared to cluster intrahepatically into two groups
(high frequencies >80%; low frequencies <70%, see supple-
mentary ﬁgure S4, available online only)—the functional conse-
quences of this are highlighted below.
In summary, despite in-situ inﬂammatory stimuli from chronic
hepatitis and HCV infection activating intrahepatic NK cells
(evidenced by downregulating certain NK cytotoxicity
receptors, increased IFNγ production and degranulation; ﬁgure
2B–D,F–I), NKp46 does not appear to be downregulated.
NKp46-rich NK populations demonstrate increased activity
with consequent pathology
The above data suggest HCV infection impinges on NKp46,
and has a direct bearing on NK cell function. Twenty-four pre-
treatment liver biopsies were available from HCV-infected sub-
jects. These were scored for the degree of necroinﬂammation
Figure 1 Peripheral blood natural killer (NK) phenotype and function in hepatitis C virus (HCV), non-viral chronic liver disease and healthy donors
(HD). (A) NK cells as a percentage of lymphocytes in the peripheral blood of HCV (10.1%) and HD (13.3% unpaired t test p=0.05) and chronic
liver diseases (CLD). (B) Comparison of NKp46 expression on peripheral blood NK cells in HCV and HD (unpaired t test p=0.06) and CLD.
(C) Degranulation (CD107a externalisation) is reduced in the HCV cohort compared to HD and CLD at low-level stimulation (50 IU/ml interferon
(IFN)α and Huh7.5 target cells, p=0.006, unpaired t test) and HD at high-level stimulation (1000 IU/ml IFNα overnight and K562 target cells,
p=0.017). (D) NK cytotoxic function correlates with baseline NKp46 expression in the HCV cohort (left panel p=0.0068, r2=0.29) but not the
HD or CLD cohorts (right panel p=ns). Mean and SEM shown. PBMC, Peripheral blood mononuclear cells.
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(NI score); representative histology slides demonstrating lower
and higher NI scores are shown (ﬁgure 3A). Portal tract inﬂam-
mation is a striking feature of HCV infection; specialised stains
for NKp46 and CD3 highlighted this portal inﬂammation, con-
ﬁrming the inﬂux of NKp46+ NK cells are focused on the
portal areas (ﬁgure 3B). This relationship between the frequency
Figure 2 Intrahepatic and peripheral blood natural killer (NK) cell phenotype and function. (A) NK cells as a percentage of lymphocytes in the
peripheral blood and intrahepatic compartments of hepatitis C virus (HCV) and chronic liver disease (CLD) donors (left panel). The correlation of NK
cells in the blood and intrahepatic compartments of HCV and CLD donors (p=0.0007, r2=0.4 and p=0.024, r2=0.23, respectively, right panel).
(B) Representative ﬂuorescence-activated cell sorter (FACS) plots of CD16 expression on NK cells in the peripheral blood mononuclear cell (PBMC)
and the intrahepatic compartments (ﬁne needle aspiration; FNA). NK cell CD16 expression is reduced in the intrahepatic compartment in the HCV
and CLD cohorts (p>0.0001). (C) NKp30 expression is reduced in the intrahepatic compartment in the HCV and CLD cohorts (p<0.0001). (D) NKG2D
expression is reduced in the intrahepatic compartment in the HCV cohort (p=0.01) but not in the CLD cohort. (E) NKp46 expression is not
signiﬁcantly different in the intrahepatic and peripheral blood compartments. Correlation of peripheral blood and intrahepatic NKp46 expression in
the HCV and CLD cohorts (p<0.0001, r2=0.68). (F) Representative FACS plots of NK cell CD107a externalisation and intracellular granzyme B from
peripheral blood and FNA. (G) Intracellular granzyme B is reduced in NK cells from the intrahepatic compartment in both the HCV (p=0.0003) and
CLD cohorts (p=0.0016). (H) CD107a is increased in the intrahepatic compartment in the HCV (p=0.006) and CLD (p=0.002) cohorts. (I) Interferon
(IFN)γ production is increased in NK cells in the intrahepatic compartments in the HCV (p=0.0002) and CLD (p=0.0015) cohorts. Mean and SEM
shown.
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of intrahepatic NKp46+ NK cells (measured by ﬂow cytometry)
and hepatic inﬂammation (scored histologically) is demonstrated
by the correlation with overall liver inﬂammation (using NI
scores, p=0.007, Spearman’s r=0.55; ﬁgure 3C, left panel) and
even more signiﬁcantly with portal inﬂammation score
(p=0.004, Spearman’s r=0.59; ﬁgure 3C, right panel).
Importantly, in the CLD cohort (n=22) there was no association
between NK cell phenotype, including NKp46 and functional
Figure 3 NKp46-rich natural killer (NK) cell populations are more active and correlate with liver inﬂammation in chronic hepatitis C virus (HCV).
(A) Representative H&E stain liver biopsies. Left panel—necroinﬂammatory score of 3 (*=portal tract,→=periportal inﬂammation, score=2,
◄=focal hepatitis, score=1) 30% NK cells NKp46+. Right panel—necroinﬂammatory score of 8, (periportal inﬂammation=3, interface hepatitis
within broken circle=3, focal hepatitis=2) 92% NK cells NKp46+. (B) DAB immunohistochemistry of a portal tract from a HCV-infected individual
demonstrating representative staining of NKp46+ cells (left panel two examples denoted by ) and CD3+ cells (right panel, 2 examples denoted by
). (C) %NKp46+ NK cells correlates with necroinﬂammatory score (p=0.007 Spearman’s r=0.55), and in particular with portal inﬂammation
(p=0.004, Spearman’s r=0.59). (D) NKp46-rich intrahepatic NK populations have increased CD107a externalisation (left panel p=0.006) and reduced
intracellular granzyme B in the HCV cohort (right panel p=0.01). (E) Reduction in peripheral blood NKp46+ NK cells after high-level stimulation and
degranulation and necroinﬂammatory score. Mean and SEM shown. FNA, Fine needle aspiration; PBMV, peripheral blood mononuclear cells.
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markers and liver inﬂammation; suggesting an HCV-speciﬁc,
rather than a general inﬂammatory process associating with
NKp46 (data not shown).
An increased frequency of NKp46+ NK cells in blood is asso-
ciated with increased activation (degranulation) on stimulation
in vitro only in HCV-infected subjects (ﬁgure 1D). NKp46-rich
intrahepatic NK cell populations are associated with more active
liver inﬂammation (ﬁgure 3C). The possibility remained that an
increase in these intrahepatic NK cells was a result of preferen-
tial trafﬁcking of NKp46+ cells to the inﬂamed liver or upregu-
lation of NKp46 within the inﬂamed liver. If this was the case
we might expect to see a relative enrichment of NKp46+ cells
compared to peripheral blood, but this was not seen. As stated
above, there is a strong correlation between intrahepatic and
peripheral blood NKp46 expression (ﬁgure 2E) with the levels
within each subject, irrespective of the degree of liver inﬂamma-
tion, matching between compartments. To address this further,
NK cell function was examined directly ex vivo. As outlined
above, the proportion of intrahepatic NK cells expressing
NKp46 separated the HCV cohort into two distinct clusters
(NKp46-rich: ≥80% NKp46+ cells and NKp46-poor: ≤70%
NKp46+ cells; ﬁgure 2E and supplementary ﬁgure S4, available
online only). The NKp46-rich intrahepatic NK cell population
demonstrated an increased activation compared to the
NKp46-poor population as marked by degranulation (CD107a
increased, p=0.006; ﬁgure 3D, left panel panel; intracellular
granzyme B decreased, p=0.01; ﬁgure 3D, right panel). It has
recently been demonstrated that the unknown ligand for
Figure 4 Intrahepatic and peripheral blood natural killer (NK) cells during the ﬁrst 12 weeks of interferon (IFN)α treatment and NKp46+
population correlates with rate of viral clearance. (A) Representative rates of viral decline: Rapid response to IFNα treatment with reduction in viral
load k=0.67. Slow viral response with k=−0.2 and no response to treatment k<−1.5. (B) Percentage of peripheral blood NK cells that are NKp46+
and rate of viral decline during IFNα treatment (p=0.01, r2=0.36). (C) Functional ratio inversely correlates with percentage of NK cells that are
NKp46+ (p=0.005, r2=0.29) (D). Functional ratio correlates with rate of viral clearance (p=0.029, r2=0.3). (E) Patients who clear HCV with IFNα
treatment have lower expression of NKp46 at baseline than those who fail treatment (p=0.048). (F) Variations in NK cells as percentage of
lymphocytes during the ﬁrst 12 weeks of IFNα treatment in the peripheral blood and intrahepatic compartments (n=9). Proportion of intrahepatic
NK cells increases at day 1 and day 3 (paired t test pretreatment and day 1 p=0.023 and pretreatment and day 3 p=0.021). (G) Percentage of
CD16+. (H) Percentage of CD107a externalisation. (I) Percentage of NKp46+. FNA, Fine needle aspiration; PBMC, peripheral blood mononuclear cells;
SVR, sustained viral response.
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NKp46 in HCV infection is expressed in vitro by a hepatoma
cell line transfected with the JFH-1 HCV strain.18 This ﬁnding
suggests that NKp46+ NK cells have the potential to be acti-
vated directly by HCV-infected hepatocytes. Overall, these data
strongly support the notion that in-situ increased activation of
NKp46-rich populations in the context of chronic HCV infec-
tion are a driving force in liver inﬂammation. We hypothesised
that persistent overexpression of NKp46 within the NK popula-
tion may allow these cells to engage continuously with putative
activating ligands in vivo contributing to liver pathology.
NKp46 is downregulated on NK cell activation in healthy indi-
viduals (see supplementary ﬁgure S3C, available online only).
However, in HCV infection there appears to be a potential loss
of this homeostatic mechanism in some individuals; individuals
with the highest levels of liver inﬂammation (NI score) fail to
downregulate NKp46 in ex-vivo degranulation assays at
maximal stimulation (ﬁgure 3E). These data suggest that the
mechanism of HCV-related immunopathology is a failure of
intrinsic homeostatic NK cell attenuation within the chronically
infected liver.
The relationship between IFNα treatment with blood
and intrahepatic NKp46+ NK cells
Preliminary data suggested baseline NKp46 expression might
inﬂuence the rate of viral clearance.17 We extended this study
using serial blood samples in 17 subjects to calculate the rate of
viral clearance (k in day−1) for each subject (examples shown in
ﬁgure 4A). Indeed, the frequency of NKp46+ NK cells pretreat-
ment did inversely correlate with the rate of viral clearance
(p=0.01, r2=0.36; ﬁgure 4B), which is a strong predictor of
HCV treatment success.19 So it appears that individuals with a
high frequency of NKp46+ NK cells, which we have shown are
more activated at baseline (ﬁgure 3C,D) are those least able to
control the virus on IFNα treatment. This observation is borne
out by measuring the capacity of the NK cells to increase their
response from a weaker stimulus (Huh7.5 plus 50 IU/ml IFNα)
to that of a stronger stimulus (K562 plus 1000 IU/ml IFNα);
this increase is calculated as a functional ratio=% CD107a+
with strong stimulus÷% CD107a+ with a weak stimulus (as out-
lined in the Methods section). The functional ratio correlated
inversely to the percentage of NKp46+ cells (p=0.005,
r2=0.29; ﬁgure 4C) and there was a positive correlation with
the rate of viral clearance (p=0.029, r2=0.3; ﬁgure 4D). In
summary, NKp46 expression dictates the relative ability of NK
cells to respond to increasing IFNα stimulation, which in turn
reﬂects their ability to clear HCV rapidly during treatment. In
keeping with this we found that individuals who achieved SVR
following IFNα and ribavirin treatment had a lower mean fre-
quency of NKp46+ NK cells than individuals who failed treat-
ment (72% and 80.5%, respectively p=0.048, ﬁgure 4E).
Finally, having established the methodology for comparing
side-by-side intrahepatic and blood-derived NK cell populations,
we proceeded to obtain serial biopsies from nine patients with
repeated FNA sampling at multiple time points during the ﬁrst
12 weeks of treatment (ﬁgure 4F–I). After 12 weeks, seven
patients had undetectable viral loads by PCR (and six of these
eventually achieved an SVR) and two had no response to treat-
ment. IFNα induced a signiﬁcant increase in intrahepatic NK
cells at days 1 and 3, but was not altered from baseline at later
time points (p=0.008 repeated measures analysis of variance).
The intrahepatic NK cells approximately doubled over 3 days
(ﬁgure 4F) from the baseline mean of 10% (day 1
mean=16.0%, p=0.02; day 3 mean=17.8%, p=0.02; paired t
test). Changes in percentage of CD16+, CD107a+ and NKp46+
(ﬁgure 4G–I) that occurred at days 1 and 3 returned to baseline
by day 7. These changes occurred in the intrahepatic NK cells,
and suggested activation with a small increase in CD107a and
decrease in CD16. Again the behaviour of NKp46 was unex-
pected in as much as it actually increased at day 1. These
changes overall were of a small magnitude, and there were no
discernible differences in the changes measured prospectively in
NK cell phenotype between the rapid responders and those who
failed treatment in this cohort. However, an inability to distin-
guish between recent liver emigrants and the established intrahe-
patic NK cell population potentially masks signiﬁcant alterations
in the resident NK cell population.
DISCUSSION
In HCV infection chronic liver inﬂammation results in ﬁbrosis,
cirrhosis and increases the risk of hepatocellular carcinoma.
There is some evidence that NK cells are an important compo-
nent of the innate immune response to HCV.5 9 11–13 The ﬁnd-
ings of this study corroborate the ﬁndings of Ahlenstiel et al,
5
supporting an important role for NK cell cytotoxic function in
contributing to the rapid early decline in viral load, a predictor
of successful treatment. The data are also in keeping with our
previous ﬁndings, which demonstrated that rapid viral clearance
effectively abrogates the need and/or the ability to mount an
adaptive immune response.17 This is in keeping with evidence
from mouse models that highly active NK cells can clear viral
antigen before adaptive immune priming.20 21 However, failure
of both innate and CD4 T-cell responses to IFNα results in
treatment failure.17
In this paper we further investigated NK cell activity in both
blood and liver of HCV-infected individuals. We have utilised a
FNA technique for sampling intrahepatic NK cells, which has
allowed repeated sampling of the same individual at multiple
time points during IFNα-based treatment of HCV for the ﬁrst
time. In order to reduce contamination from peripheral lympho-
cytes the needle is inserted 2–4 cm in an attempt to avoid punc-
ture of the larger central branches of veins or arteries; any
markedly bloody samples were discarded and the procedure
repeated. FNA NK cells demonstrated a highly signiﬁcant shift in
phenotype and functional markers (ﬁgure 2). However, as the
liver is an extremely vascular organ there remains the possibility
that some of the lymphocytes may have been sampled from small
blood vessels within the liver capsule rather than within the liver
parenchyma itself. NK cells were initially reported to account for
30–50% of lymphocytes within the intrahepatic compartment.22
However, we found that this proportion was lower and strongly
correlated with the proportion of NK cells in the peripheral
blood (mean 10.5% and 9.6%, respectively, ﬁgure 2A). These
proportions of CD3+ and NKp46+ lymphocytes were similar on
immunohistological staining (ﬁgure 3B). The lower proportion
of intrahepatic NK cells is in keeping with the ﬁndings of mul-
tiple studies, which report a mean intrahepatic NK cell propor-
tion ranging from 2.7% to 18%.7 11 13 14 23 24 NK cells with a
high frequency of NKp46 expression, termed NKp46 rich, from
the intrahepatic compartment of HCV-infected subjects have a
more activated phenotype. In line with this, we found signiﬁ-
cantly higher necroinﬂammatory scores were observed in
NKp46-rich individuals. The ligands of activating receptors such
as NKp30 and NKp46 are poorly characterised. Viral haemagglu-
tinins from inﬂuenza, ectromelia and vaccinia viruses have been
shown to engage with NKp30 and/or NKp46.25 26 In vaccinia
infection, the viral haemagglutinin actually blocks NKp30 activa-
tion. In addition, NKp30 has also been shown to bind to a stress
ligand B7-H6 expressed on tumour cells including the K562
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cells.27 The presence of the ligand for NKp46 has been identiﬁed
on HCV-infected hepatocytes indirectly using NKp46-Fc fusion
proteins, but the nature of the actual ligand is unknown.18
Considering these results, it is striking that during IFNα treat-
ment the ability to respond robustly to the increasing level of
stimulation from IFNα is found in individuals with NKp46-poor
NK populations, in whom there is an associated rapid decline in
viral load and treatment success. This presents a paradox that
patients most in need of treatment (high inﬂammation, greatest
long-term risk) may be more difﬁcult to treat.
Two recent studies have identiﬁed NKp46High NK cells as also
being more activated in HCV infection.13 18 In these studies NK
cell subpopulations were deﬁned using the level of NKp46
expression on a per-cell basis using the mean ﬂuorescence inten-
sity (MFI). These studies suggest that on the basis of in-vitro
assays, these NKp46High cells have greater antiviral activity. We
found that NKp46 expression, based on MFI, formed a single
population (rather than two discrete high and low subpopula-
tions) in 40% of our cohort, which may relate to methodo-
logical differences between the studies (see supplementary ﬁgure
S6A, available online only). However, we do ﬁnd NKp46 MFI
correlates strongly with the percentage of NKp46+ cells
(p<0.0001, see supplementary ﬁgure S6B, available online
only). We also ﬁnd NKp46 is associated with NK cells with
greater cytoxic potential in vitro (ﬁgure 1D) and increased acti-
vation measured ex vivo (ﬁgure 3D). However, cytotoxic/anti-
viral activity measured in vitro does not translate to in-vivo
treatment-induced control of the virus. It is the ability to
ncrease NK cell activity signiﬁcantly i(ie, the functional ratio
shown in ﬁgure 4C,D), as found in NKp46-poor populations, as
a potentially abrupt escalation of the cytotoxic attack that is
important. This concept of relative response to IFNα is in
keeping with previous ﬁndings of interferon-stimulated genes
(ISG) in chronic HCV infection suggesting a common theme to
treatment resistance. Individuals with low ISG expression before
treatment who have marked upregulation of ISG on initiation of
IFNα are more likely to achieve SVR than those with high ISG
expression pretreatment.28–30
Measurement of the frequency of NKp46+ NK cells might
serve as a biomarker to help predict treatment outcome. NKp46
may serve two purposes in the development of HCV treatment
strategies as a therapeutic target. First, blockade of NKp46
might reduce NK cell activity before IFNα treatment and
improve the subsequent NK cell response. Second, NKp46
blockade may reduce inﬂammation as a long-term treatment
goal in those unable to undergo IFNα treatment. We are cur-
rently conducting studies to explore these ideas.
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